These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2011412)

  • 1. Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor.
    Sasson S
    Pathol Biol (Paris); 1991 Jan; 39(1):59-69. PubMed ID: 2011412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of antiestrogens with human breast cancer in long-term tissue culture.
    Lippman M; Bolan G; Huff K
    Cancer Treat Rep; 1976 Oct; 60(10):1421-9. PubMed ID: 1035504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inhibition of estrogen and antiestrogen binding to the estrogen receptor by diethylpyrocarbonate.
    Borgna JL; Scali J
    J Steroid Biochem; 1988 Oct; 31(4A):427-36. PubMed ID: 3050278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
    Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
    Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of putative estrogens with the intracellular receptor complex in mouse Leydig cells: relationship to preneoplastic hyperplasia.
    Juriansz RL; Huseby RA; Wilcox RB
    Cancer Res; 1988 Jan; 48(1):14-8. PubMed ID: 3334987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxy or counterpart function with the estrogen receptor.
    Borgna JL; Scali J
    Eur J Biochem; 1991 Aug; 199(3):575-85. PubMed ID: 1868844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of the estrogen receptor interaction with 4-hydroxytamoxifen.
    Sasson S; Notides AC
    Mol Endocrinol; 1988 Apr; 2(4):307-12. PubMed ID: 3380103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiestrogen pharmacology and mechanism of action.
    Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K
    J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estriol and estrone interaction with the estrogen receptor. II. Estriol and estrone-induced inhibition of the cooperative binding of [3H]estradiol to the estrogen receptor.
    Sasson S; Notides AC
    J Biol Chem; 1983 Jul; 258(13):8118-22. PubMed ID: 6863280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The unusual binding properties of the third distinct teleost estrogen receptor subtype ERbetaa are accompanied by highly conserved amino acid changes in the ligand binding domain.
    Hawkins MB; Thomas P
    Endocrinology; 2004 Jun; 145(6):2968-77. PubMed ID: 15001543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of free DNA on the interactions of the estrogen receptor bound to hormone, partial antagonist or pure antagonist with target DNA.
    Aliau S; Groblewski T; Borgna JL
    Eur J Biochem; 1995 Jul; 231(1):204-13. PubMed ID: 7628472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model for the effect of estrogen antagonists on cooperative estradiol binding.
    Porrelli RN; Munson PJ; Rodbard D
    J Recept Res; 1993; 13(7):1055-81. PubMed ID: 8366504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties.
    Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL
    J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
    Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
    Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol.
    Melamed M; Castaño E; Notides AC; Sasson S
    Mol Endocrinol; 1997 Nov; 11(12):1868-78. PubMed ID: 9369454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Sem Hop; 1984 Mar; 60(10):703-9. PubMed ID: 6322320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture.
    Lippman M; Monaco ME; Bolan G
    Cancer Res; 1977 Jun; 37(6):1901-7. PubMed ID: 870192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogens and antiestrogens mediate contrasting transitions in estrogen receptor conformation which determine chromatin access: a review and synthesis of recent observations.
    Nelson K; van Nagell JR; Gallion H; Donaldson ES; Pavlik EJ
    Prog Clin Biol Res; 1988; 262():85-104. PubMed ID: 3287392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.